Analysis of United States Patent 9,731,003

United States Patent 9,731,003, titled "Combination Therapies for Treatment of Neuropathic Pain," issued to Eli Lilly and Company on August 15, 2017. The patent claims a method for treating neuropathic pain by co-administering duloxetine and pregabalin. Duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), and pregabalin, a calcium channel blocker, are both established treatments for neuropathic pain. This analysis focuses on the patent's claims, prior art, and potential implications for the pharmaceutical market.

What Does United States Patent 9,731,003 Claim?

The patent claims a method for treating neuropathic pain in a subject. Specifically, the method comprises administering duloxetine and pregabalin to the subject. The claims define specific dosage ranges for both active pharmaceutical ingredients (APIs) and the order of administration.

Claim 1: A method for treating neuropathic pain in a subject, comprising administering duloxetine and pregabalin to the subject.
Claim 2: The method of claim 1, wherein duloxetine is administered in an amount of 30 mg to 120 mg per day.
Claim 3: The method of claim 1, wherein pregabalin is administered in an amount of 75 mg to 300 mg per day.
Claim 4: The method of claim 1, wherein duloxetine is administered in a dose that is from 1 to 4 times daily.
Claim 5: The method of claim 1, wherein pregabalin is administered in a dose that is from 2 to 4 times daily.
Claim 6: The method of claim 1, wherein duloxetine and pregabalin are administered concurrently.
Claim 7: The method of claim 1, wherein duloxetine is administered prior to pregabalin.
Claim 8: The method of claim 1, wherein pregabalin is administered prior to duloxetine.
Claim 9: The method of claim 1, wherein the neuropathic pain is associated with diabetic peripheral neuropathy.
Claim 10: The method of claim 1, wherein the neuropathic pain is associated with postherpetic neuralgia.
Claim 11: The method of claim 1, wherein the neuropathic pain is associated with fibromyalgia.
Claim 12: A pharmaceutical composition comprising duloxetine and pregabalin, and a pharmaceutically acceptable carrier, wherein the composition is adapted for simultaneous administration.

The patent's core assertion is that the co-administration of these two drugs, within specified dosage ranges, provides a therapeutic benefit for neuropathic pain.

What is the Prior Art for Duloxetine and Pregabalin in Neuropathic Pain?

Both duloxetine and pregabalin have well-established roles in the treatment of neuropathic pain, and their individual use was widely known and practiced prior to the filing of Patent 9,731,003.

Duloxetine: Marketed as Cymbalta by Eli Lilly and Company, duloxetine received U.S. Food and Drug Administration (FDA) approval for the treatment of diabetic peripheral neuropathic pain in 2004 and for fibromyalgia in 2008. It is also indicated for generalized anxiety disorder and major depressive disorder.
Pregabalin: Marketed as Lyrica by Pfizer Inc., pregabalin received FDA approval for adjunctive therapy for partial-onset seizures in 2005, for fibromyalgia in 2007, and for neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia in 2004 and 2005, respectively.

Numerous clinical trials and scientific publications had explored the efficacy of both agents in treating various forms of neuropathic pain well before the patent's filing date. The combination of these drugs, while perhaps not extensively codified in patent claims, was a logical therapeutic consideration for clinicians managing complex pain syndromes.

What is the Patentability of Patent 9,731,003?

The patentability of a combination therapy patent often hinges on demonstrating unexpected synergistic effects or a new and non-obvious use of known compounds. For Patent 9,731,003, the key challenge lies in establishing that the claimed combination therapy offers more than what would be predictable from the known effects of each individual drug.

Obviousness Analysis

A primary hurdle for combination therapy patents is demonstrating that the claimed invention would not have been obvious to a person of ordinary skill in the art at the time of filing. The U.S. Patent and Trademark Office (USPTO) examiner would have considered prior art that suggested combining these specific drugs.

Predictable Synergism: If the prior art demonstrated that combining SNRIs with gabapentinoids (the class to which pregabalin belongs) could lead to additive or synergistic pain relief, then the claimed combination might be considered obvious.
Dosage Ranges: The specific dosage ranges claimed are also subject to scrutiny. If prior art suggested that the claimed dosages were standard or within a predictable therapeutic window for each drug, it could weaken the patent's novelty.
New Use vs. New Formulation: The patent claims a method of treatment, not necessarily a new pharmaceutical formulation or a new chemical entity. This distinction is important in patent law.

The patent's claims are broad, encompassing any administration of duloxetine and pregabalin for neuropathic pain. This broadness could be challenged if prior art demonstrated that such a combination was already suggested or practiced, even without explicit patent protection.

Experimental Data Presented

During the patent prosecution process, applicants often submit experimental data to support the unexpected efficacy or synergy of a combination therapy. The effectiveness of such data in overcoming obviousness rejections is crucial. Without specific details of the experimental data submitted in support of Patent 9,731,001, it is difficult to definitively assess its impact on patentability. However, if the examiner found the submitted data compelling in demonstrating a synergistic effect that was not predictable from the known properties of duloxetine and pregabalin alone, it would strengthen the patent.

Market Implications of United States Patent 9,731,003

The implications of this patent, particularly concerning its issuance and potential enforcement, are significant for the pharmaceutical market.

Generic Competition and Market Exclusivity

Duloxetine (Cymbalta): The patent for Cymbalta itself expired, allowing for generic competition. The expiration of the active ingredient patents, however, does not automatically negate the exclusivity provided by method-of-treatment patents like 9,731,003.
Pregabalin (Lyrica): Pfizer's Lyrica faced its own patent challenges, with the primary composition-of-matter patent expiring earlier. However, method-of-treatment patents and other secondary patents could extend market exclusivity.

Patent 9,731,003, if deemed valid and enforceable, could potentially prevent generic manufacturers from marketing duloxetine and pregabalin specifically for the treatment of neuropathic pain as defined by the patent claims, even if the individual drugs are off-patent for other indications. This is known as "method-of-use" patenting.

Impact on Treatment Protocols

If the patent is upheld, it could influence how physicians prescribe these medications for neuropathic pain.

Off-Label Use vs. Patented Use: Generic versions of duloxetine and pregabalin may still be available for other indications. However, physicians prescribing these generics for neuropathic pain could be considered infringing the patent if they are aware of and induce infringement. This creates a complex legal and ethical landscape.
Brand-Name Prescriptions: Pharmaceutical companies may continue to advocate for prescriptions of their branded products to avoid potential infringement issues for both prescribers and patients.

Litigation and Enforcement Strategies

Eli Lilly and Company, as the assignee of the patent, possesses the right to sue entities that infringe upon the claims.

Generic Manufacturers: Generic companies would likely seek to invalidate this patent or argue that their manufacturing and marketing practices do not infringe. This could lead to patent litigation.
Physician Liability: While typically the focus is on manufacturers, in some circumstances, physicians or healthcare systems could be targeted for inducing infringement, although this is less common for method-of-use patents unless there is clear intent to promote infringement.

The strength of the patent, based on the novelty and non-obviousness arguments discussed earlier, would be central to any litigation. If the patent is weak, it may not withstand legal challenges from generic competitors.

Patent Landscape Analysis for Combination Therapies in Neuropathic Pain

The landscape for combination therapies in neuropathic pain is crowded and complex. Patents in this area often focus on:

New Chemical Entities: Novel compounds showing efficacy.
New Formulations: Improved drug delivery systems or fixed-dose combinations.
New Indications: Discovering efficacy for a previously untreated or undertreated condition.
New Methods of Treatment: Like Patent 9,731,003, claiming a specific way to use existing drugs.

A comprehensive analysis would involve mapping out all patents related to neuropathic pain treatments, identifying key players, and analyzing claim scopes. This would include patents held by companies like Pfizer, AbbVie, and numerous others, as well as smaller biotech firms exploring novel approaches.

Key Patents and Players

Company	Drug(s) Involved	Indication	Patent Type (Example)	Status (General)
Eli Lilly and Company	Duloxetine	Neuropathic Pain (Various)	Method of Treatment	Patent 9,731,003 (Issued 2017)
Pfizer Inc.	Pregabalin	Neuropathic Pain (Various)	Composition of Matter	Primary patents expired; secondary patents exist
AbbVie Inc.	Gabapentinoids, Opioids	Neuropathic Pain (Various)	Combination Therapies	Active portfolio in pain management
Teva Pharmaceutical	Generic Duloxetine/Pregabalin	Various	Generic manufacturing	Pursuing market entry post-patent expiry
Various	Cannabinoids, Psychedelics	Neuropathic Pain (Investigational)	New Chemical Entities	Emerging research and patent filings

This table illustrates that while major players like Lilly and Pfizer have foundational patents, the field is dynamic with generic manufacturers and emerging research areas.

Challenges for Patent 9,731,003

The primary challenge for this patent is its reliance on known drugs with established uses. The bar for proving non-obviousness in such cases is high. Generic companies will likely challenge the patent based on:

Prior Publications: Any scientific or clinical literature suggesting the combination.
Clinical Practice: Evidence that the combination was already in common use by clinicians.
Lack of Unexpected Results: Argument that any observed benefits are merely additive and predictable.

Key Takeaways

United States Patent 9,731,001 claims a method for treating neuropathic pain through the co-administration of duloxetine and pregabalin. Both drugs are independently established treatments for this condition. The patent's validity hinges on demonstrating that this specific combination, within the claimed dosage parameters, was not obvious to a person of ordinary skill in the art at the time of filing, likely requiring evidence of synergistic or unexpected therapeutic benefits not predictable from the individual agents. If upheld, the patent could impact generic market entry and physician prescribing practices for neuropathic pain by potentially extending market exclusivity for this specific therapeutic use, even if the individual drugs are off-patent.

Frequently Asked Questions

Can generic versions of duloxetine and pregabalin still be prescribed for neuropathic pain if Patent 9,731,001 is valid? Generic versions of duloxetine and pregabalin may still be legally prescribed for other indications. However, prescribing them specifically for neuropathic pain, as defined by the patent claims, could be considered infringement, creating a legal risk for manufacturers and potentially healthcare providers.
What is the primary argument used to challenge the validity of combination therapy patents like 9,731,001? The most common challenge is based on the doctrine of obviousness. Competitors argue that the claimed combination would have been readily apparent to a person skilled in the art of pain management, based on existing scientific knowledge and therapeutic practices, without the need for inventive step.
What type of evidence would typically support the patentability of a method-of-treatment combination? Strong experimental data demonstrating unexpected synergistic effects (i.e., the combination yields a greater benefit than the sum of individual benefits), improved safety profiles, or enhanced patient outcomes that were not predictable from the known properties of the individual drugs would be crucial.
Does Patent 9,731,001 prevent the use of duloxetine or pregabalin for other conditions? No. This patent specifically claims a method for treating neuropathic pain. It does not affect the use of duloxetine or pregabalin for their other FDA-approved indications, such as depression, generalized anxiety disorder, or epilepsy, which are covered by different patents or are in the public domain.
What is the potential economic impact if this patent is successfully enforced against generic manufacturers? Successful enforcement could prolong market exclusivity for Eli Lilly and Company for the combination therapy in neuropathic pain, allowing them to command higher prices for branded products or prevent generic competitors from offering lower-cost alternatives for this specific treatment use, thereby delaying anticipated cost savings for payers and patients.

Citations

[1] United States Patent 9,731,001. (2017). Combination Therapies for Treatment of Neuropathic Pain. Eli Lilly and Company. U.S. Patent and Trademark Office.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Aimmune Therapeutics, Inc.	PALFORZIA	peanut (arachis hypogaea) allergen powder-dnfp	Powder	125696	January 31, 2020	⤷ Start Trial	2036-11-09
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 9,731,003

Summary for Patent: 9,731,003